



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

May 21, 2019

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the board of directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Standalone audited financial results for the year ended on March 31, 2019 alongwith Auditors' Report.
2. Consolidated audited financial results for the year ended on March 31, 2019 alongwith Auditors' Report.
3. Declaration of Unmodified opinion on report issued by auditors of the Company M/s. D N V & Co., Chartered Accountants on annual Standalone audited financial statement as well as annual Consolidated audited financial statement.

These financial results have been approved and taken on record by the board of directors at its meeting held today.


The meeting of the Board of Directors commenced at 12.15 p.m. and concluded at 3.55 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited



M.C. Mehta

Company Secretary and Vice President - Compliance

📍 **Registered Office:**

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED


STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON MARCH 31, 2019

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2019	31-12-2018	31-03-2018	31-03-2019	31-03-2018	31-03-2019	31-03-2018
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	37,914.77	35,192.83	31,847.43	150,118.70	125,420.37	164,320.04	141,298.15
2	Other Income	1,528.85	1,557.92	1,145.55	4,022.50	3,578.58	4,143.99	3,710.75
3	Total Income (1+2)	39,443.62	36,750.75	32,992.98	154,141.20	128,998.95	168,464.03	145,008.90
4	Expenses							
a.	Cost of materials consumed	11,774.30	11,049.81	11,771.17	45,375.37	38,701.68	45,375.37	38,701.68
b.	Purchases of stock-in-trade	2,702.54	2,346.28	727.51	10,426.13	9,304.46	16,209.91	15,739.56
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	98.18	(1,964.69)	(159.59)	(2,165.74)	(38.81)	(1,939.38)	(659.41)
d.	Employee benefit expenses	6,758.24	6,475.90	5,538.30	25,797.86	21,730.93	28,817.59	25,109.87
e.	Finance Costs	85.78	126.93	95.12	411.51	341.36	419.81	349.21
f.	Depreciation and amortization expense	1,140.81	1,448.54	1,304.30	5,482.49	5,594.85	5,564.20	5,697.37
g.	Other Expenses	10,634.35	10,042.28	10,036.19	41,886.05	35,460.18	45,317.27	40,675.56
	Total Expenses (4)	33,194.20	29,525.05	29,313.00	127,213.67	111,094.65	139,764.77	125,613.84
5	Profit before Tax (3-4)	6,249.42	7,225.70	3,679.98	26,927.53	17,904.30	28,699.26	19,395.06
6	Tax expenses	2,031.91	2,588.35	1,474.05	8,721.61	5,104.16	9,302.29	5,523.12
7	Net Profit after Tax for the period (5-6)	4,217.51	4,637.35	2,205.93	18,205.92	12,800.14	19,396.97	13,871.94
8	Other Comprehensive Income (net of Tax)	214.66	(61.80)	(147.84)	29.25	(241.63)	(419.64)	(18.08)
9	Total Comprehensive Income after Tax (7+8)	4,432.17	4,575.55	2,058.09	18,235.17	12,558.51	18,977.33	13,853.86
10	Net Profit after Tax for the period attributable to:							
	- owners of the company	-	-	-	-	-	19,346.63	13,834.09
	- non controlling interest	-	-	-	-	-	50.34	37.85
11	Total Comprehensive Income after Tax attributable to:							
	- owners of the company	-	-	-	-	-	18,974.19	13,794.73
	- non controlling interest	-	-	-	-	-	3.14	59.13
12	Earning per share (EPS) (of Rs. 2/- each not annualised)							
(1) Basic		5.13	5.64	2.63	22.15	15.24	23.54	16.48
(2) Diluted		5.13	5.64	2.63	22.15	15.24	23.54	16.48

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 21, 2019.
- The Board of Directors has recommended a dividend of Rs. 5/- per equity share of face value of Rs. 2/- (250%).
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Effective July 1, 2017, sales are recorded net of GST where as earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the year ended March 31, 2019 are not comparable with previous year corresponding figures.
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2018-19.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2019 is as under:

Particulars	Standalone		Consolidated	
	As at	As at	As at	As at
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	54,254.09	55,993.76	54,441.67	56,371.11
(b) Capital work-in-progress	1,508.99	1,740.23	1,508.99	1,740.23
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	957.01	997.01	2,337.75	2,265.23
(e) Financial Assets				
(i) Investments	22,884.24	18,292.47	9,587.56	4,995.79
(ii) Trade receivables	-	-	-	-
(iii) Loans	358.86	332.67	358.86	332.67
(iv) Others	15.82	15.11	15.82	15.11
(f) Other non-current assets	577.87	755.07	577.87	755.07
TOTAL non current assets	80,556.88	78,126.32	74,142.52	71,789.21



Registered Office:
 Neelam Centre, B Wing, 4th Floor
 Hind Cycle Road, Worli
 Mumbai - 400 030

Corporate Office:
 Energy IT Park
 Unit A2, 3rd Floor, Unit A, 8th Floor
 Appa Saheb Marathe Marg, Prabhadevi
 Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
 ☎ +91 22 2431 5331 / 2431 5334
 @ info@jbcpl.com
 🌐 www.jbcpl.com
 CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II) Current assets				
(a) Inventories	20,810.42	17,581.44	24,375.76	21,373.14
(b) Financial Assets				
(i) Investments	36,064.99	38,376.60	36,064.99	38,376.60
(ii) Trade receivables	30,092.38	30,054.05	30,929.53	30,072.96
(iii) Cash and cash equivalents	1,936.77	1,297.29	3,539.68	2,794.28
(iv) Bank balances other than (iii) above	140.03	198.04	140.03	198.04
(v) Loans	70.95	104.86	140.23	177.61
(vi) Others	1,476.34	89.26	1,505.22	89.35
(c) Current Tax Assets (Net)	666.22	806.28	715.06	829.46
(d) Other current assets	7,396.56	10,052.93	7,547.03	10,809.81
TOTAL current assets	98,654.66	98,560.75	104,957.53	104,721.25
Total Assets	179,211.54	176,687.07	179,100.05	176,510.46
EQUITY AND LIABILITIES				
Equity				
(a) Equity Share capital	1,604.73	1,671.40	1,604.73	1,671.40
(b) Other Equity	146,851.50	143,667.41	146,407.51	142,484.40
(c) non controlling interest			280.33	277.18
Total Equity	148,456.23	145,338.81	148,292.57	144,432.98
LIABILITIES				
(I) Non-current liabilities				
(a) Provisions	572.89	967.36	572.89	967.36
(b) Deferred tax liabilities (Net)	7,115.12	4,970.15	5,690.73	3,238.58
(c) Other non-current liabilities	220.29	360.01	220.29	360.01
TOTAL non current liabilities	7,908.30	6,297.52	6,483.91	4,565.95
(II) Current liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,579.77	2,847.62	2,579.77	2,929.28
(ii) Trade payables				
A) Dues to Micro and Small Enterprises	787.01	74.50	787.01	74.50
B) Due to Other than Micro and Small Enterprises	6,884.33	9,947.60	7,489.05	10,965.00
(iii) Other financial liabilities	10,424.65	10,141.03	11,000.19	10,814.82
(b) Other current liabilities	1,646.80	1,148.76	1,676.17	1,160.14
(c) Provisions	134.09	891.23	397.72	1,552.50
(d) Current Tax Liabilities (Net)	390.36	-	393.66	15.29
TOTAL current liabilities	22,847.01	25,050.74	24,323.57	27,511.53
Total Equity and Liabilities	179,211.54	176,687.07	179,100.05	176,510.46

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 21/05/2019



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Independents Auditors' Report on Quarter and Annual Standalone Financial Results of the J. B. Chemicals and Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
J. B. Chemicals and Pharmaceuticals Limited

1. We have audited the accompanying Statement of Standalone Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Company"), for the Quarter and year ended March 31, 2019 together with the notes thereon ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initialed by us for the purpose of identification.
2. This Statement, which is the responsibility of the Company's Management approved by the Board of Directors at its meetings held on May 21, 2019, has been compiled from the related standalone financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such standalone financial statements.
3. We conducted our audits in accordance with the Auditing Standards generally accepted in India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the standalone financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the management.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.



+91 22 6149 1000  www.dnvca.com

14/2, Mahalaxmi Ind. Estate, D. Shivner Road, Lower Parel, Mumbai - 400 013, India.
Branch : Pune

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 ; and
 - give a true and fair view in conformity with the Ind AS and other accounting principles generally accepted in India, of the net profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.
5. The Statement includes the results for the Quarter ended March 31, 2019, being the balancing figure between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For D N V & Co.

Chartered Accountants


Firm Registration No. 100583

Bharat

CA Bharat Jain

Partner

Membership No: 100583



Place: Mumbai

Date: May 21, 2019



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON MARCH 31, 2019

(Rs. in lakhs)


Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2019	31-12-2018	31-03-2018	31-03-2019	31-03-2018	31-03-2019	31-03-2018
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	37,914.77	35,192.83	31,847.43	150,118.70	125,420.37	164,320.04	141,298.15
2	Other Income	1,528.85	1,557.92	1,145.55	4,022.50	3,578.58	4,143.99	3,710.75
3	Total Income (1+2)	39,443.62	36,750.75	32,992.98	154,141.20	128,998.95	168,464.03	145,008.90
4	Expenses							
a.	Cost of materials consumed	11,774.30	11,049.81	11,771.17	45,375.37	38,701.68	45,375.37	38,701.68
b.	Purchases of stock-in-trade	2,702.54	2,346.28	727.51	10,426.13	9,304.46	16,209.91	15,739.56
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	98.18	(1,964.69)	(159.59)	(2,165.74)	(38.81)	(1,939.38)	(659.41)
d.	Employee benefit expenses	6,758.24	6,475.90	5,538.30	25,797.86	21,730.93	28,817.59	25,109.87
e.	Finance Costs	85.78	126.93	95.12	411.51	341.36	419.81	349.21
f.	Depreciation and amortization expense	1,140.81	1,448.54	1,304.30	5,482.49	5,594.85	5,564.20	5,697.37
g.	Other Expenses	10,634.35	10,042.28	10,036.19	41,886.05	35,460.18	45,317.27	40,675.56
	Total Expenses (4)	33,194.20	29,525.05	29,313.00	127,213.67	111,094.65	139,764.77	125,613.84
5	Profit before Tax (3-4)	6,249.42	7,225.70	3,679.98	26,927.53	17,904.30	28,699.26	19,395.06
6	Tax expenses	2,031.91	2,588.35	1,474.05	8,721.61	5,104.16	9,302.29	5,523.12
7	Net Profit after Tax for the period (5-6)	4,217.51	4,637.35	2,205.93	18,205.92	12,800.14	19,396.97	13,871.94
8	Other Comprehensive Income (net of Tax)	214.66	(61.80)	(147.84)	29.25	(241.63)	(419.64)	(18.08)
9	Total Comprehensive Income after Tax (7+8)	4,432.17	4,575.55	2,058.09	18,235.17	12,558.51	18,977.33	13,853.86
10	Net Profit after Tax for the period attributable to:							
	- owners of the company	-	-	-	-	-	19,346.63	13,834.09
	- non controlling interest	-	-	-	-	-	50.34	37.85
11	Total Comprehensive Income after Tax attributable to:							
	- owners of the company	-	-	-	-	-	18,974.19	13,794.73
	- non controlling interest	-	-	-	-	-	3.14	59.13
12	Earning per share(EPS) (of Rs. 2/- each not annualised)							
(1) Basic		5.13	5.64	2.63	22.15	15.24	23.54	16.48
(2) Diluted		5.13	5.64	2.63	22.15	15.24	23.54	16.48

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 21, 2019.
- The Board of Directors has recommended a dividend of Rs. 5/- per equity share of face value of Rs. 2/- (250%).
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Effective July 1, 2017, sales are recorded net of GST where as earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the year ended March 31, 2019 are not comparable with previous year corresponding figures.
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2018-19.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2019 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at March 31, 2019	As at March 31, 2018	As at March 31, 2019	As at March 31, 2018
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	54,254.09	55,993.76	54,441.67	56,371.11
(b) Capital work-in-progress	1,508.99	1,740.23	1,508.99	1,740.23
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	957.01	997.01	2,337.75	2,265.23
(e) Financial Assets				
(i) Investments	22,884.24	18,292.47	9,587.56	4,995.79
(ii) Trade receivables	-	-	-	-
(iii) Loans	358.86	332.67	358.86	332.67
(iv) Others	15.82	15.11	15.82	15.11
(f) Other non-current assets	577.87	755.07	577.87	755.07
TOTAL non current assets	80,556.88	78,126.32	74,142.52	71,789.21



Registered Office:

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II)	Current assets				
	(a) Inventories	20,810.42	17,581.44	24,375.76	21,373.14
	(b) Financial Assets				
	(i) Investments	36,064.99	38,376.60	36,064.99	38,376.60
	(ii) Trade receivables	30,092.38	30,054.05	30,929.53	30,072.96
	(iii) Cash and cash equivalents	1,936.77	1,297.29	3,539.68	2,794.28
	(iv) Bank balances other than (iii) above	140.03	198.04	140.03	198.04
	(v) Loans	70.95	104.86	140.23	177.61
	(vi) Others	1,476.34	89.26	1,505.22	89.35
	(c) Current Tax Assets (Net)	666.22	806.28	715.06	829.46
	(d) Other current assets	7,396.56	10,052.93	7,547.03	10,809.81
	TOTAL current assets	98,654.66	98,560.75	104,957.53	104,721.25
	Total Assets	179,211.54	176,687.07	179,100.05	176,510.46
	EQUITY AND LIABILITIES				
	Equity				
	(a) Equity Share capital	1,604.73	1,671.40	1,604.73	1,671.40
	(b) Other Equity	146,851.50	143,667.41	146,407.51	142,484.40
	(c) non controlling interest			280.33	277.18
	Total Equity	148,456.23	145,338.81	148,292.57	144,432.98
	LIABILITIES				
(I)	Non-current liabilities				
	(a) Provisions	572.89	967.36	572.89	967.36
	(b) Deferred tax liabilities (Net)	7,115.12	4,970.15	5,690.73	3,238.58
	(c) Other non-current liabilities	220.29	360.01	220.29	360.01
	TOTAL non current liabilities	7,908.30	6,297.52	6,483.91	4,565.95
(II)	Current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	2,579.77	2,847.62	2,579.77	2,929.28
	(ii) Trade payables				
	A) Dues to Micro and Small Enterprises	787.01	74.50	787.01	74.50
	B) Due to Other than Micro and Small Enterprises	6,884.33	9,947.60	7,489.05	10,965.00
	(iii) Other financial liabilities	10,424.65	10,141.03	11,000.19	10,814.82
	(b) Other current liabilities	1,646.80	1,148.76	1,676.17	1,160.14
	(c) Provisions	134.09	891.23	397.72	1,552.50
	(d) Current Tax Liabilities (Net)	390.36	-	393.66	15.29
	TOTAL current liabilities	22,847.01	25,050.74	24,323.57	27,511.53
	Total Equity and Liabilities	179,211.54	176,687.07	179,100.05	176,510.46

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 21/05/2019

(Handwritten signature)



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380

Independent Auditors' Report on the Annual Consolidated Financial Results of the J. B. Chemicals and Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
J. B. Chemicals and Pharmaceuticals Limited

1. We have audited the accompanying Statement of Consolidated Financial Results of J. B. Chemicals and Pharmaceuticals Limited ("the Holding Company") and its Subsidiaries (the Holding Company and Its subsidiaries together referred to as ("the JBCPL Group")), for the year ended 31st March, 2019 together with the notes thereon ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initialed by us for the purpose of identification.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, at its meeting held on May 21, 2019, has been compiled from the related annual consolidated financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such consolidated financial statements.
3. We conducted our audits in accordance with the Auditing Standards generally accepted in India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the management.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.



4. In Our opinion and to the best of our information and according to the explanations given to us, based on the consideration of the reports of the other auditors on standalone financial statements / consolidated financial statements and the other information of subsidiaries referred to in paragraph below, the Statement:

Includes financial results of the following subsidiaries:


- a) List of Subsidiaries:
- i. 000 Unique Pharmaceutical Laboratories,
 - ii. Unique Pharmaceutical Laboratories FZE and
 - iii. Biotech Laboratories (Pty.) Ltd (Subsidiary of Unique Pharmaceutical Laboratories FZE)
- b) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- c) give a true and fair view in conformity with the Ind AS and other accounting principles generally accepted in India of the consolidated net profit, consolidated total comprehensive Income and other financial information of the JBCPL Group for the year ended March 31, 2019.
5. We did not audit the financial statements / financial information of the subsidiaries referred in paragraph 4 (a) above included in the consolidated financial results, whose standalone financial statements/ consolidated financial statements and financial information reflect total assets of Rs 21,258.02 Lakhs as at March 31, 2019, total revenue of Rs 26,251.37 Lakhs and net cash inflow of Rs 482.07 Lakhs for the year ended on that date. These financial statements/consolidated financial statements and other information have been audited by other auditors whose reports have been furnished to us by the management, and our opinion on the consolidated financial results in so far as relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors.

Our opinion on the Statement is not modified in respect of above matters with regards to our reliance on the work done and the reports of the other auditors.

For D N V & Co.

Chartered Accountants

Firm Registration No. 102079W


CA Bharat Jain
Partner
Membership No: 100583

Place: Mumbai

Date: May 21, 2019



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED ON MARCH 31, 2019

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended		Consolidated Year ended	
		31-03-2019	31-12-2018	31-03-2018	31-03-2019	31-03-2018	31-03-2019	31-03-2018
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Revenue from Operations	37,914.77	35,192.83	31,847.43	150,118.70	125,420.37	164,320.04	141,298.15
2	Other Income	1,528.85	1,557.92	1,145.55	4,022.50	3,578.58	4,143.99	3,710.75
3	Total Income (1+2)	39,443.62	36,750.75	32,992.98	154,141.20	128,998.95	168,464.03	145,008.90
4	Expenses							
a.	Cost of materials consumed	11,774.30	11,049.81	11,771.17	45,375.37	38,701.68	45,375.37	38,701.68
b.	Purchases of stock-in-trade	2,702.54	2,346.28	727.51	10,426.13	9,304.46	16,209.91	15,739.56
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	98.18	(1,964.69)	(159.59)	(2,165.74)	(38.81)	(1,939.38)	(659.41)
d.	Employee benefit expenses	6,758.24	6,475.90	5,538.30	25,797.86	21,730.93	28,817.59	25,109.87
e.	Finance Costs	85.78	126.93	95.12	411.51	341.36	419.81	349.21
f.	Depreciation and amortization expense	1,140.81	1,448.54	1,304.30	5,482.49	5,594.85	5,564.20	5,697.37
g.	Other Expenses	10,634.35	10,042.28	10,036.19	41,886.05	35,460.18	45,317.27	40,675.56
	Total Expenses (4)	33,194.20	29,525.05	29,313.00	127,213.67	111,094.65	139,764.77	125,613.84
5	Profit before Tax (3-4)	6,249.42	7,225.70	3,679.98	26,927.53	17,904.30	28,699.26	19,395.06
6	Tax expenses	2,031.91	2,588.35	1,474.05	8,721.61	5,104.16	9,302.29	5,523.12
7	Net Profit after Tax for the period (5-6)	4,217.51	4,637.35	2,205.93	18,205.92	12,800.14	19,396.97	13,871.94
8	Other Comprehensive Income (net of Tax)	214.66	(61.80)	(147.84)	29.25	(241.63)	(419.64)	(18.08)
9	Total Comprehensive Income after Tax (7+8)	4,432.17	4,575.55	2,058.09	18,235.17	12,558.51	18,977.33	13,853.86
10	Net Profit after Tax for the period attributable to:							
	- owners of the company	-	-	-	-	-	19,346.63	13,834.09
	- non controlling interest	-	-	-	-	-	50.34	37.85
11	Total Comprehensive Income after Tax attributable to:							
	- owners of the company	-	-	-	-	-	18,974.19	13,794.73
	- non controlling interest	-	-	-	-	-	3.14	59.13
12	Earning per share (EPS) (of Rs. 2/- each not annualised)							
(1)	Basic	5.13	5.64	2.63	22.15	15.24	23.54	16.48
(2)	Diluted	5.13	5.64	2.63	22.15	15.24	23.54	16.48

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on May 21, 2019.
- The Board of Directors has recommended a dividend of Rs. 5/- per equity share of face value of Rs. 2/- (250%).
- The amount of damage caused due to explosion/fire on July 6, 2018 at Company's API unit at Panoli, Gujarat is being assessed by the Insurance Company. The Company believes that the final loss, when determined on due completion of process, will not materially impact the financials.
- Effective July 1, 2017, sales are recorded net of GST where as earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the year ended March 31, 2019 are not comparable with previous year corresponding figures.
- The Company has one reportable segment viz. Pharmaceuticals.
- Figures pertaining to last quarter are balancing figures between audited figures in respect of full financial year and published and reviewed year-to-date figures up to the third quarter of the financial year 2018-19.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- The statement of assets and liabilities as on March 31, 2019 is as under:

(Rs. in lakhs)

Particulars	Standalone		Consolidated	
	As at	As at	As at	As at
	March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
ASSETS				
(I) Non-current assets				
(a) Property, Plant and Equipment	54,254.09	55,993.76	54,441.67	56,371.11
(b) Capital work-in-progress	1,508.99	1,740.23	1,508.99	1,740.23
(c) Goodwill	-	-	5,314.00	5,314.00
(d) Other Intangible assets	957.01	997.01	2,337.75	2,265.23
(e) Financial Assets				
(i) Investments	22,884.24	18,292.47	9,587.56	4,995.79
(ii) Trade receivables	-	-	-	-
(iii) Loans	358.86	332.67	358.86	332.67
(iv) Others	15.82	15.11	15.82	15.11
(f) Other non-current assets	577.87	755.07	577.87	755.07
TOTAL non current assets	80,556.88	78,126.32	74,142.52	71,789.21



Registered Office:
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

Corporate Office:
Cnergy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

(II)	Current assets				
	(a) Inventories	20,810.42	17,581.44	24,375.76	21,373.14
	(b) Financial Assets				
	(i) Investments	36,064.99	38,376.60	36,064.99	38,376.60
	(ii) Trade receivables	30,092.38	30,054.05	30,929.53	30,072.96
	(iii) Cash and cash equivalents	1,936.77	1,297.29	3,539.68	2,794.28
	(iv) Bank balances other than (iii) above	140.03	198.04	140.03	198.04
	(v) Loans	70.95	104.86	140.23	177.61
	(vi) Others	1,476.34	89.26	1,505.22	89.35
	(c) Current Tax Assets (Net)	666.22	806.28	715.06	829.46
	(d) Other current assets	7,396.56	10,052.93	7,547.03	10,809.81
	TOTAL current assets	98,654.66	98,560.75	104,957.53	104,721.25
	Total Assets	179,211.54	176,687.07	179,100.05	176,510.46
	EQUITY AND LIABILITIES				
	Equity				
	(a) Equity Share capital	1,604.73	1,671.40	1,604.73	1,671.40
	(b) Other Equity	146,851.50	143,667.41	146,407.51	142,484.40
	(c) non controlling interest		280.33		277.18
	Total Equity	148,456.23	145,338.81	148,292.57	144,432.98
	LIABILITIES				
(I)	Non-current liabilities				
	(a) Provisions	572.89	967.36	572.89	967.36
	(b) Deferred tax liabilities (Net)	7,115.12	4,970.15	5,690.73	3,238.58
	(c) Other non-current liabilities	220.29	360.01	220.29	360.01
	TOTAL non current liabilities	7,908.30	6,297.52	6,483.91	4,565.95
(II)	Current liabilities				
	(a) Financial Liabilities				
	(i) Borrowings	2,579.77	2,847.62	2,579.77	2,929.28
	(ii) Trade payables				
	A) Dues to Micro and Small Enterprises	787.01	74.50	787.01	74.50
	B) Due to Other than Micro and Small Enterprises	6,884.33	9,947.60	7,489.05	10,965.00
	(iii) Other financial liabilities	10,424.65	10,141.03	11,000.19	10,814.82
	(b) Other current liabilities	1,646.80	1,148.76	1,676.17	1,160.14
	(c) Provisions	134.09	891.23	397.72	1,552.50
	(d) Current Tax Liabilities (Net)	390.36	-	393.66	15.29
	TOTAL current liabilities	22,847.01	25,050.74	24,323.57	27,511.53
	Total Equity and Liabilities	179,211.54	176,687.07	179,100.05	176,510.46

For J.B. Chemicals & Pharmaceuticals Ltd

J.B. Mody
Chairman & Managing Director

Place : Mumbai
Date : 21/05/2019

(Handwritten signature)



📍 **Registered Office:**
Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**
Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500
✉ +91 22 2431 5331 / 2431 5334
@ info@jbcpl.com
🌐 www.jbcpl.com
CIN: L24390MH1976PLC019380



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

May 21, 2019

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Declaration pursuant to SEBI notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 read with circular CIR/CFD/CMD/56/2016 dated May 27, 2016.

This is to inform you that auditors of the Company M/s. D N V & Co., Chartered Accountants, have issued their report on annual Standalone audited financial statement as well as annual Consolidated audited financial statement, for the year ended March 31, 2019.

We hereby state & declare that the above two audit reports have been issued with unmodified opinion.

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta

Company Secretary and Vice President - Compliance

📍 **Registered Office:**

Neelam Centre, B Wing, 4th Floor
Hind Cycle Road, Worli
Mumbai - 400 030

📍 **Corporate Office:**

Energy IT Park
Unit A2, 3rd Floor, Unit A, 8th Floor
Appa Saheb Marathe Marg, Prabhadevi
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380